Therapeutic Outlook in DLBCL: Evaluating Treatment Sequencing from Front-line to Relapsed Refractory Disease - Episode 12
Academic Insights for the Treatment of Later Relapsed/Refractory DLBCL
An overview of third-line treatment options for DLBCL, including choices for patients who did not receive CAR T-cell therapy or transplant in second-line, strategies for those who progress after CAR T-cell or transplant, and the impact of bispecific antibodies and ADCs, with insights from key studies on Glofit and Epcor in relapsed/refractory DLBCL and their implications for patient selection and care.
Video content above is prompted by the following:
Please discuss current trials using bispecific antibody therapies in DLBCL.
Briefly discuss the available third-line (3L) options for treatment of DLBCL.
- Dr Miklos: What would you choose for patients that did not receive CAR T-cell therapy or transplant in the 2L?
- Dr Ghosh:What if patients progress after receiving CAR T-cell therapy or transplant in the 2L?
- Discuss the rationale for bispecific antibodies or antibody drug conjugates.
Dr Abdulhaq:Given the findings from bispecific antibodies in RR DLBCL, along with the FDA 3L approval of Glofit, how will 3L treatment choices change?
- Elaborate on the key takeaways from Glofit in RR DLBCL (Dickinson et el. NEJM 2022) and Epcor in RR DLBCL (Thieblemont et al. JCO 2022).
- ALL:How do these studies inform your care, and what patients are best suited for this type of regimen?
- When making treatment choices, what are the key differentiators between the two approved options that you consider?